Objective
to investigate the 1-year clinical outcomes of pulmonary artery denervation (PADN) as compared to sham procedure for the treatment of pulmonary arterial hypertension (PAH)
Study
multicentre, sham-controlled, randomised trial
Population
group I pulmonary arterial hypertension (WHO). PAH: m PAP ⥠25mm Hg, pulmonary vascular resistance > 3 woods units and pulmonary arterial wedge pressure < 15mm Hg
Endpoints
clinical worsening : composite of worsening PAH, atrial septostomy, listing for lung transplantation or all-cause death at 1 year
Conclusion
among patients with group I pulmonary arterial hypertension PADN resulted in a significant reduction in 1-year clinical worsening compared to sham procedure
Kan et al. EuroIntervention 2023; 19: online July
